Astria Therapeutics (ATXS) Projected to Post Earnings on Monday

Astria Therapeutics (NASDAQ:ATXS) will likely be posting its quarterly earnings results before the market opens on Monday, March 3rd. Analysts expect Astria Therapeutics to post earnings of ($0.45) per share for the quarter.

Astria Therapeutics Stock Performance

NASDAQ:ATXS opened at $6.44 on Friday. Astria Therapeutics has a one year low of $6.20 and a one year high of $16.90. The firm has a market cap of $363.43 million, a P/E ratio of -3.08 and a beta of 0.67. The firm has a 50-day simple moving average of $7.70 and a 200-day simple moving average of $9.89.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. JMP Securities assumed coverage on shares of Astria Therapeutics in a report on Friday, January 31st. They issued an “outperform” rating and a $26.00 price target for the company. HC Wainwright restated a “buy” rating and issued a $16.00 price target on shares of Astria Therapeutics in a report on Thursday. Citizens Jmp raised shares of Astria Therapeutics to a “strong-buy” rating in a research report on Friday, January 31st. Finally, Oppenheimer lifted their price objective on shares of Astria Therapeutics from $26.00 to $28.00 and gave the stock an “outperform” rating in a research report on Thursday, November 14th. Six research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Buy” and an average target price of $25.67.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.